Advertisement
U.S. markets open in 7 hours 10 minutes

Novozymes A/S (NVZMY)

Other OTC - Other OTC Delayed Price. Currency in USD
56.24+0.25 (+0.45%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close55.99
Open56.05
BidN/A x N/A
AskN/A x N/A
Day's Range55.98 - 56.33
52 Week Range38.75 - 56.33
Volume28,148
Avg. Volume14,767
Market Cap26.115B
Beta (5Y Monthly)0.48
PE Ratio (TTM)35.59
EPS (TTM)1.58
Earnings DateN/A
Forward Dividend & Yield1.19 (2.11%)
Ex-Dividend DateOct 20, 2023
1y Target Est64.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NVZMY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NOVOZYMES A/S UNSP ADR EACH REP
    Analyst Report: Coloplast A/SColoplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed

    Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024Company announcement No. 07 On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination") was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024. As previously announ

  • GlobeNewswire

    Legacy Novozymes delivers solid last full-year results

    Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality. COPENHAGEN, Denmark – February 1, 2024. In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before specia

  • GlobeNewswire

    Results update for 2023 – unaudited

    6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation As Novozymes just closed the combination with Chr. Hansen on January 29, and the annual report now is expected to be released on February 8, this announcement only contains unaudited numbers. Full audited financial statements as well as non-financial numbers will be released with the annual report on February 8. This result update allows us to provide selected numbers for Novozymes standalone